Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna Launches 3 New Vaccine Programs Beyond Coronavirus

AstraZeneca

Johnson & Johnson

Pfizer

This past Friday brought the U.S. its largest single-day amount of Covid-19 cases since the pandemic began in earnest back in March of last year: 310K in a single 24-hour period.

Racing Against Time: Covid-19 vs. Vaccines

Moderna, the biotech company behind one of the two mRNA-based vaccines currently being rolled out globally to stem the tide of COVID-19, has announced that it will purse development programs around three new vaccine candidates in 2021. These include potential vaccines for HIV, seasonal flu and the Nipah virus.

Moderna is developing three new mRNA-based vaccines for seasonal flu, HIV and Nipah virus

Shares of Moderna Inc. were up 1.3% in premarket trading on Monday after the company said it plans to launch new development programs using its mRNA technology that will focus on developing vaccines for seasonal flu, HIV, and the Nipah virus. This follows the success of its mRNA COVID-19 vaccine, which is one of two vaccines to be authorized so far in the U.S. CEO Moderna also said it plans to expand its respiratory syncytial virus to include older adults, and it plans to test different vaccine combinations that fight the flu, COVID-19, RSV, and human metapneumovirus.

Moderna to develop vaccine candidates for seasonal flu, HIV

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna Provides Business Update and Announces Three New Development Programs in Infectious Disease Vaccines

Moderna Provides Business Update and Announces Three New Development Programs in Infectious Disease Vaccines

Peloton

Block

Teladoc

Zoom Video

The 5 Best Coronavirus Stocks to Buy Now

Seagen

Vertex, Inc.

Revenue growth is just beginning for these companies.

The Top 3 Biotech Stocks to Buy in 2021

HEXO Corp

Stimulus checks could be just what investors need to be a part of the high-flying market.

Got $600? Here Are the Top Growth Stocks to Buy Now

Moderna Inc. (NASDAQ: MRNA) reported this Friday that its COVID-19 vaccine has been approved for emergency use by the United Kingdom's medicines regulator. Despite this, Moderna shares are still trading significantly lower than the high of $178.50 per share in early December.

Moderna shares remain in a bull market but the current price does not represent a good value for long-term investors

Kuehne + Nagel will provide global warehousing and distribution for Moderna Inc.'s (NASDAQ: MRNA) new COVID-19 vaccine, the Swiss third-party logistics powerhouse said Thursday. The news follows Wednesday's approval by the European Commission for the drug to be administered on a conditional basis.

Kuehne + Nagel lands global logistics deal for Moderna COVID-19 vaccine

MRNA stock will continue to slowdown as its Covid 19 vaccine gains are priced-in and with the competiton chomping away at its market share The post As Competition Rises, the Bull Case for Moderna Stock Is Beginning to Fade appeared first on InvestorPlace. More From InvestorPlace Why Everyone Is Investing in 5G All WRONG Top Stock Picker Reveals His Next 1,000% Winner Radical New Battery Could Dismantle Oil Markets

As Competition Rises, the Bull Case for Moderna Stock Is Beginning to Fade

British government agrees to buy additional 10 million doses of two-shot Moderna vaccine taking the total to 17 million.

Moderna's COVID-19 vaccine becomes third shot authorized for use in U.K.

Blueprint Medicines

Halozyme Therapeutics

We highlight a few biotech companies, which outperformed the sector in 2020 and are likely to witness a winning run in the near term.

3 Biotech Stocks Worth Adding to Your Portfolio in 2021

Moderna Inc. (NASDAQ: MRNA) said on Friday that it secured emergency use authorisation from the United Kingdom's medicines' regulator for its COVID-19 vaccine. It is the third vaccine that received a green light from Britain.

UK's MHRA approves Moderna's COVID-19 vaccine for emergency use

Biotech Moderna's COVID-19 vaccine has been authorized for emergency use by U.K. regulators, bringing a third shot to the country that is battling a surge in coronavirus cases. The Medicines and Healthcare products Regulatory Agency, or MHRA, approved the vaccine after a "thorough and rigorous assessment" by the regulator's teams of scientists, including advice from the independent Commission on Human Medicines, the government said in a statement on Friday.

Moderna's COVID-19 vaccine becomes third to be authorized by U.K. regulator

The UK approved Moderna's COVID-19 vaccine Friday, making it the third coronavirus shot to be rolled out in the country. The COVID-19 vaccine, which works in a similar way to the Pfizer shot, was given regulatory approval for supply by the Medicines and Healthcare products Regulatory Agency (MHRA), according to a statement by the UK government.

Moderna's COVID-19 vaccine becomes the third shot approved for use in the UK

CAMBRIDGE, Mass.--(BUSINESS WIRE)--United Kingdom Medicines and Healthcare products Regulatory Agency Authorizes Use of COVID-19 Vaccine Moderna

United Kingdom Medicines and Healthcare products Regulatory Agency Authorizes Use of COVID-19 Vaccine Moderna

Moderna's coronavirus vaccine has become the third approved for use in the U.K.

UK regulator approves Moderna Covid vaccine

Stephane Bancel is convinced mRNA-1273 can keep the coronavirus at bay for a great many months.

Moderna CEO Says Its Coronavirus Vaccine Could Be Effective for Years

Moderna's vaccine for Covid-19 proves its operating system for creating new drugs works. That means more growth is ahead for MRNA stock.

Moderna Is An Example of Why You Should Buy Systems, Not Drugs

Amgen

Moderna Inc (NASDAQ: MRNA), which received the fourth regulatory nod for its investigational coronavirus vaccine with the conditional approval granted Wednesday by the European Union, is leaving no stone unturned in its commercialization efforts. What Happened: Boston, Massachusetts-based Moderna said it has hired biopharma industry veteran Corinne Le Goff as chief commercial officer effective Jan. 19.

Moderna Hires Amgen Executive As Chief Commercial Officer To Bolster Vaccine Marketing

As one of the leaders in the Covid-19 vaccine race, Moderna's success boosted MRNA stock. But with real-time obstacles coming into the picture, the narrative moving forward isn't as exciting.

Vaccine Backlog Raises New Questions About Moderna

2020 was saved thanks to Pfizer Inc. (NYSE: PFE) and Moderna Inc (NASDAQ: MRNA) whose vaccines against COVID-19 helped us see the light at the end of the pandemic tunnel. But unlike Pfizer with its rich long history in vaccines, Moderna became a household name only after its mRNA-1273 became the second COVID-19 vaccine approved for emergency use.

Moderna Has Big Plans For 2021

Shares of Moderna Inc. were down 0.2% in trading on Thursday after the company said it had hired an Amgen executive to run commercial operations as it rolls out the first doses of its COVID-19 vaccine, in the U.S. and elsewhere. Corinne Le Goff, a pharmacist by trade and the former president of the U.S. business at Amgen Inc. , will begin her role as chief commercial officer on Jan. 19, reporting to CEO Stéphane Bancel.

Moderna hires Amgen executive as chief commercial officer

Moderna (MRNA) gets conditional use authorization for coronavirus vaccine, mRNA-1273, for use in adults in EU member states.

News for Moderna Stock (MRNA)